CBS: Alibaba probe found drug sales, but DOJ avoided prosecution
A CBS News investigation found U.S. prosecutors had evidence Alibaba and its payment arm knowingly allowed dangerous drugs, chemicals, and pill presses to reach American buyers for eight years, yet the Justice Department resolved the case with a $600 million settlement and no felony prosecution. The deal lets the Chinese e-commerce giant and AUS Merchant Services avoid criminal charges while admitting to lesser misdemeanor violations.
Key Takeaways
- CBS News reported prosecutors believed they had enough evidence to prove felony violations of the Federal Food, Drug and Cosmetic Act.
- Alibaba and AUS Merchant Services agreed to pay $600 million under non-prosecution agreements rather than face indictment.
- Between 2016 and 2024, roughly 80,000 illegal sales on Alibaba.com and AliExpress.com exceeded $200 million in gross merchandise value.
- Employees warned Alibaba that compliance controls were inadequate, public records cited by CBS show.
- The case is part of a broader pattern in which senior DOJ leaders have softened or dropped similar public-health prosecutions.
What Did CBS Uncover About Alibaba's Drug Sales?
For eight years, Chinese online retailer Alibaba and its U.S. payment processor failed to prevent dangerous drugs, chemicals, and pill presses from being sold to American customers, even after employees warned of compliance problems, CBS News reported.
Sources told CBS that prosecutors believed they had sufficient evidence to prove felony violations of the Food, Drug and Cosmetic Act. Career prosecutors urged Justice Department leadership to pursue a deferred prosecution agreement in which the companies would admit to felony offenses.
According to the Justice Department, Alibaba admitted that between January 2016 and December 2024 it failed to stop about 80,000 product sales involving illegal pharmaceuticals, controlled substances, listed chemicals, and pill-making equipment imported through Alibaba.com and AliExpress.com. Federal investigators conducted more than 40 undercover purchases during the probe.
Why Did the DOJ Settle Instead of Prosecute?
Instead of the tougher deferred prosecution path career prosecutors favored, the case was resolved with a non-prosecution agreement in which Alibaba and AUS admitted only to lesser misdemeanor violations, CBS News reported. Multiple sources familiar with the matter said the decision fits a recent pattern of corporate public-health cases being softened, dismissed, or losing support from senior Justice Department leaders.
A department spokesperson told CBS News that ensuring food supply safety is a priority for the Trump administration but added, "this Department of Justice does not believe in regulation by prosecution."
The settlement highlights rising scrutiny of how e-commerce and digital payment platforms police third-party merchants—a recurring theme in our Fintech & Crypto Alerts coverage.
How Much Did Alibaba and Its Payment Processor Pay?
Under the non-prosecution agreements announced in July 2026, Alibaba and AUS Merchant Services will pay a combined $600 million in penalties and forfeitures, the Justice Department said. Both companies accepted responsibility for acts by officers, directors, employees, and agents.
They also committed to enhanced compliance programs and continued cooperation with ongoing or future criminal investigations. The Wall Street Journal reported that Alibaba.com admitted to failing to prevent the roughly 80,000 sales, and that the agreement includes a non-prosecution clause reflecting its cooperation with the investigation.
What Does This Mean for U.S. Consumers?
Assistant U.S. Attorney General Brett Shumate said the resolution reflects the department's commitment to keeping illegal and dangerous foreign pharmaceuticals off online marketplaces. Yet CBS News reporting raises questions about whether financial penalties alone deter repeat misconduct when felony charges are taken off the table.
Al Jazeera reported that at times Alibaba employees raised concerns about whether illegal products were being sold and whether compliance measures were inadequate. AUS's anti-money-laundering program also failed to prevent some merchants from using its services to facilitate banned imports. For Americans buying health products online, the case underscores the risks of unregulated imports—and the limits of enforcement when settlements replace prosecution.